Immunoconjugates targeting CD138 and uses thereof

US9387261B2 · kind B2 · utility

Assignees

• Biotest AG · DE
• IMMUNOGEN, INC. · US

Inventors

• Elmar Kraus · Bad Vilbel, DE
• Christoph Bruecher · Eschborn, DE
• Benjamin Daelken · Frankfurt am Main, DE
• Steffen Zeng · Munster, DE
• Frank Osterroth · Dietzenbach, DE
• Christoph Uherek · Seligenstadt, DE
• Silke Aigner · Bischofswerda, DE
• Matthias Germer · Langen, DE
• Gregor Schulz · Umkirch, DE
• Thomas Haeder · Dreieich, DE

Key dates

• Filing date: Dec 23, 2008
• Grant date: Jul 12, 2016
• Expiry date: Jul 25, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.